ResearchMoz

Avastin (Breast Cancer) Analysis and Forecasts to 2020

GlobalData
Published Date » 2011-12-31
No. Of Pages » 47
 GlobalDatas pharmaceuticals report, Avastin (Breast Cancer)  Analysis and Forecasts to 2020 provides Avastin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.  Note: This is a on-demand...
Table of Contents

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Analysis and Estimates Report Guidance 7

3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 10
3.3.4 Decreasing Breast Cancer Mortality Rate 11
3.3.5 High Survival Rates of Breast Cancer 14

4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15

5 Predictive Biomarker in the Treatment of Breast Cancer 18

6 Treatment Options of Breast Cancer 20

6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 27

7 Avastin (bevacizumab) 29
7.1 Introduction 29
7.2 Mechanism of Action 29
7.3 Clinical Studies 29
7.4 Approval History of Avastin 30
7.5 Factors Affecting Sales of Avastin 31
7.5.1 Breast Cancer Market 31
7.5.2 Efficacy 31
7.5.3 Approval in Japan 31
7.5.4 Withdrawal of Approval in the US and Rejection in the UK 31
7.5.5 EMAs Verdict 31
7.6 Drug Evaluation 31
7.6.1 Drug Risk Benefit Score 31
7.6.2 Intensity of Competition 32
7.7 Sales Forecasts 32
7.7.1 Target Patient Pool of Avastin 33
7.7.2 Dosing 33
7.7.3 Market Penetration 34
7.7.4 Annual Cost of Therapy 34
7.7.5 Sales Projections of Avastin 34

8 Breast Cancer Market: Appendix 43
8.1 Market Definitions 43
8.2 Abberiviations 43
8.3 Research Methodology 43
8.3.1 Coverage 44
8.3.2 Secondary Research 44
8.3.3 Forecasting 44
8.3.4 Number of Patients Approved to take the Drug 44
8.3.5 Net Penetration of Drug 45
8.3.6 Net Annual Dosing 46
8.3.7 Annual Cost of Therapy 46
8.3.8 Primary Research 46
8.3.9 Expert Panels 46
8.4 Contact Us 47
8.5 Disclaimer 47
8.6 Sources 47

List of Tables


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Table 3: Five-Year Relative Survival Rates, By Stages 14
Table 4: Phase III Clinical Study (E2100) Results for Avastin in Metastatic Breast Cancer 29
Table 5: Approval History of Avastin 30
Table 6: Drug Risk Benefit Score of Avastin 32
Table 7: Avastin, Breast Cancer, The US, The UK, France, Germany, Italy and Spain, Sales Estimates ($m), 20072010 35
Table 8: Avastin, Breast Cancer, France, Germany, Italy, Spain and Japan, Sales Forecasts ($m), 20072020 35
Table 9: Avastin, Breast Cancer, The US, Sales Estimates ($m) 20082010 36
Table 10: Avastin, Breast Cancer, The UK, Sales Estimates ($m) 20072010 37
Table 11: Avastin, Breast Cancer, France, Sales Forecasts ($m) 2007-2020 38
Table 12: Avastin, Breast Cancer, Germany, Sales Forecasts ($m) 20072020 39
Table 13: Avastin, Breast Cancer, Italy, Sales Forecasts ($m) 20072020 40
Table 14: Avastin, Breast Cancer, Spain, Sales Forecasts ($m) 20072020 41
Table 15: Avastin, Breast Cancer, Japan, Sales Forecasts ($m) 20112020 42

List of Figures


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top Ten Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 12: Broad Classification of Breast Cancer, By Type 15
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 14: Classification of Invasive Breast Cancer, By Stages 16
Figure 15: Classification of Invasive Breast Cancer, By Treatment 16
Figure 16: Classification of Metastatic or Advanced Breast Cancer 16
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17
Figure 18: Classification of Locally Advanced Breast Cancer 17
Figure 19: Metastatic Breast Cancer Classification 17
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 23: Treatment Options, DCIS Breast Cancer 20
Figure 24: Treatment Options, LCIS Breast Cancer 21
Figure 25: Treatment Options, Stages I, II and IIIA 21
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27
Figure 33: Drug Model Diagram of Avastin 33
Figure 34: Avastin, Breast Cancer, Global, Sales Forecasts ($m), 20072020 35
Figure 35: Avastin, Breast Cancer, The US, Sales Estimates ($m) 20082010 36
Figure 36: Avastin, Breast Cancer, The UK, Sales Estimates ($m) 20072010 37
Figure 37: Avastin, Breast Cancer, France, Sales Forecasts ($m) 2007-2020 38
Figure 38: Avastin, Breast Cancer, Germany, Sales Forecasts ($m) 20072020 39
Figure 39: Avastin, Breast Cancer, Italy, Sales Forecasts ($m) 20072020 40
Figure 40: Avastin, Breast Cancer, Spain, Sales Forecasts ($m) 20072020 41
Figure 41: Avastin, Breast Cancer, Japan, Sales Forecasts ($m) 20112020 42
Figure 42: Drug Model Diagram 45
Figure 43: Patients Approved for the Drug 46

Upcoming Reports:

Computed Radiography (CR) Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Computed radiography (CR) is an imaging technique that uses electromagnetic radiation such as X-rays. Computed radiography is a computer aided technique that uses irradiation process to produce three dimensional representations of scanned objects internally or externally. Computed radiography equipment is used in various applications such as medical facilities and industrial purpose. CR equipment comprises imaging plate that is made up of photostimulable phosphor. This plate is placed under body parts and then is exposed to electromagnetic irradiation such as X-ray. In...
Thermoplastic Polyolefins Market - Global Industry Analysis, Market Share, Size, Growth, Trends And Forecast, 2012 - 2018
By - Transparency Market Research
Thermoplastic polyolefins (TPOs) contains some fraction of polypropylene, polyethylene, rubber and filler (fiberglass, carbon fiber, and metal oxysulfate). The properties of a thermoplastic polyolefin’s depend greatly on the size and distribution of the microstructure. Thermoplastic polyolefins come under thermoplastic elastomers which are polymers and are processed like a thermoplastic material. They can be processed by various techniques including injection molding, profile extrusion, and thermoforming. They are usually injection molded into the desired article, though there...
Poland: cream market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the cream market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the cream market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...
Fonterra Ties Up With Beingmate to Tap into China’s Baby Food Market
Aug 28, 2014  
Fonterra Co-Operative Group Ltd. will partner with Beingmate Group Co, China’s biggest infant formula manufacturer to increase its reach in the Chinese market. The New Zealand-based company makes this move with the intent to grab a bigger market share in China after it suffered many setbacks in the food-safety scandal last year.   This partnership will also help Beingmate...
Chinas Leading Asset-Management Company Aims for IPO
Aug 28, 2014  
China’s biggest asset-management company plans to go public by the end of 2015. Chinese authorities are constantly ramping up their interests towards introducing mixed ownership to state-owned huge companies and call for more private capital investments into the economy. According to the news report, China Huarong Asset Management Co., Ltd. will collaborate with eight investors...
Warren Buffet Helps Burger King with Tim Horton Deal
Aug 27, 2014  
Renowned investor Warren Buffet plans to finance Burger King Worldwide Inc.’s acquisition of Tim Hortons Inc., the Canadian coffee chain. Berkshire Hathaway Inc., Warren Buffet’s firm will invest through preferred shares, it is speculated. Nearly 25% of the deal’s financing would be handled by Berkshire. The precise aim for Warren Buffet’s participation is yet...
Anti-UAW Workers to Form Another Union at Volkswagen Plant
Aug 27, 2014  
Employees at the Chattanooga plant of Volkswagen AG are trying to form a union of company’s salaried and hourly workers, as a means to counter the United Auto Workers Local 42 union that was established last month.  The new union is expected to force Volkswagen in rethinking and holding another vote to determine which union is favored by hourly employees. UAV had earlier...